Abstract
Background Secondary mitral regurgitation (SMR) is a condition affecting the left ventricle (LV) rather than the mitral valve (MV). If the mitral valve (MV) remains structurally unchanged, enlargement of the left ventricle (LV) or impairment of the papillary muscles (PM) can occur. Several mechanical interventions are available to dictate the resolution of MR. However, there is a lack of robust data to compare mitral valve replacement, mitral valve repair (including subvalvular repair), and transcatheter mitral valve procedures (TMVp). This study aims to compare the effectiveness and clinical outcomes of TMVp using the edge-to-edge mitral valve repair (TEER) technique and standard surgical mitral valve procedures (S-SMVp) in patients with SMR.
Methods and analysis Five cardiac surgery centres from four European countries and Japan have collaborated to create a multicentre observational registry (TEERMISO). The registry will enrol consecutive patients who underwent mechanical intervention for SMR between January 2007 and December 2023. The investigators assessed the difference between replacement and repair for both the standard surgical approach and the transcatheter procedure. The main clinical outcome will be the degree of LV remodelling as assessed by the Left Ventricular End-Diastolic Volume Index at 10 years. The study will measure several secondary endpoints, including all-cause mortality as the primary endpoint, followed by functional status, hospitalisation, neurocognition, physiological measures (echocardiographic assessment), adverse events and reoperation.
Ethics and dissemination Ethics approval was obtained in Montpellier University Hospital on 24 May 2022 (Institutional Review Board (IRB) Approval Number: IRB-MTP_2022_05_202201143). The results of the main study and each sub-analysis will be submitted for publication in a peer-reviewed journal. ClinicalTrials.gov ID: NCT05090540; IRB ID: 202201143. (Supplementary material)
Strengths and limitations of this study
This study will be conducted as a large international registry concerning interventions to correct secondary mitral regurgitation; it will provide clinicians important information about transcatheter and surgical techniques in the specific field of the secondary mitral regurgitation.
The primary outcome will offer opportunity to better predict left ventricular remodeling after the procedures.
The secondary outcomes of this study will offer opportunity to provide important information abut survival
The retrospective nature of the study is a limitation to the study design.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://register.clinicaltrials.gov/prs/beta/records
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Acronyms
- AE
- adverse event
- CABG
- coronary artery bypass surgery
- CCSC
- Canadian Cardiovascular Society Classification
- CHF
- chronic heart failure
- COAPT
- cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy
- GDMT
- Guideline-directed medical therapy
- HF
- heart failure
- ICU
- intensive care unit
- LCP
- Leaflet and chordal procedures
- LV
- left ventricle
- LVEDP
- Left ventricular end-diastolic pressure
- LVEF
- Left Ventricular Ejection Fraction
- MACE
- Major Adverse Cardiac Events
- MCG
- Medical College of Georgia
- MI
- Myocardial infarction
- MV
- mitral valve
- NYHA
- New York Heart Association
- PCI
- percutaneous coronary intervention
- PCWP
- Pulmonary capillary wedge pressure
- RCT
- randomized clinical trials
- RER
- respiratory exchange ratio
- RMA
- Restrictive mitral annuloplasty
- RPE
- rate of perceived exertion
- SMR
- Secondary mitral regurgitation
- S-SMVp
- standard surgical mitral valve procedure
- TEER
- transcatheter edge-to-edge mitral valve repair (TEER)
- TEERMISO
- transcatheter Versus Standard Surgical Mitral Valve Operation for Secondary Mitral Regurgitation
- TMVp
- transcatheter mitral valve procedure